Approved Hospital Formulary
QR Code Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:

tocilizumab

tocilizumab
Brand names: Actemra
Form Strength
SOLUTION, INTRAVENOUS 20 mg/mL


Additional Information:

Tocilizumab is Formulary-Restricted at Legacy Health.  Restrict to Infectious Disease approval 8am-5pm. ID consult team will assess the patient for appropriate inclusion/exclusion criteria. (Updated 8/2021).

Inclusion Criteria

    • Laboratory confirmed COVID-19
    • Age ≥ 18 years old
    • Receiving concomitant corticosteroid therapy (at least dexamethasone 6mg daily or equivalent)
    • Recent hospitalization (within 3 days) and/or ICU admission within 24 hours
    • Rapidly increasing oxygen needs (e.g. requiring high flow oxygen >0.4 FiO2/30 L/min O2 flow or non-invasive ventilation)
    • CRP ≥ 75 mg/L (ONE time value only at time of decompensation, do not recheck)
    • Limit to ONE dose only

Exclusion Criteria

    • Severely immunocompromised (AIDS, cancer undergoing chemo, solid or bone marrow transplant, neutropenia, serious congenital immunodeficiency)
    • On biologic immunomodulator such as etanercept, infliximab, rituximab, adalimumab, anakinra, golimumab
    • On chronic oral steroids (≥20 mg) for >2 weeks
    • Uncontrolled bacterial, fungal or non-SARS-CoV-2 viral infection
    • History of untreated latent tuberculosis or active tuberculosis infection
    • Patient at risk for GI perforation
    • ALT > 5 upper limit of normal
    • ANC < 500 cells/µL
    • Platelets < 50,000 cells/µL

 

 

 


Last updated: Jan. 11, 2022







This site is intended for the staff of Legacy Health.
While others may view accessible pages, Legacy Health makes no warranty, express or implied,
as to the use of this information outside of Legacy Health.